Bonnell Brian Michael 4
4 · ICU MEDICAL INC/DE · Filed Mar 16, 2026
Research Summary
AI-generated summary of this filing
ICU Medical (ICUI) CFO Brian Bonnell Receives Award, Sells Shares
What Happened
Brian M. Bonnell, Chief Financial Officer of ICU Medical (ICUI), had performance-based restricted stock units (PRSUs) and restricted stock units (RSUs) settle on March 15, 2026. A total of 14,648 shares were issued to him (11,400 + 3,248). To cover the resulting tax liability, 7,595 of those shares were withheld/sold at $125.85 per share, generating proceeds of $955,831 (5,800 shares = $729,930; 1,795 shares = $225,901). After withholding, Bonnell retained a net ~7,053 shares from the vesting.
Key Details
- Transaction date: March 15, 2026; Form 4 filed March 16, 2026 (filed next day).
- Issued (conversion of derivative/vest): 11,400 and 3,248 shares @ $0.00 (no purchase/exercise price).
- Withheld/sold for taxes (payment of tax liability): 5,800 shares @ $125.85 = $729,930; 1,795 shares @ $125.85 = $225,901. Total withheld/sold = 7,595 shares for $955,831.
- Net shares retained from the vesting: 14,648 issued − 7,595 withheld = 7,053 shares.
- Footnotes: PRSUs were granted 3/15/2023 and, per the compensation committee certification on 2/11/2026, were earned at 117% of target (F2). RSUs/PRSUs have no exercise price (F4, F5).
- Transaction codes: M = exercise/conversion of derivative (conversion of RSU/PRSU to shares); F = payment of exercise price or tax liability (share withholding/sale).
- Filing timeliness: report filed the day after the transactions (not marked late).
Context
This was a standard vesting and tax-withholding event (shares issued on settlement of PRSUs/RSUs, with a portion withheld/sold to satisfy tax obligations). Such tax withholding/sell-to-cover transactions are routine and do not, by themselves, imply a purchase or sale view on the company's shares. The key substantive item is the issuance of shares tied to performance (PRSUs earned at 117% of target).
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1][F2]2026-03-15+11,400→ 76,097 total - Tax Payment
Common Stock
[F1]2026-03-15$125.85/sh−5,800$729,930→ 70,297 total - Exercise/Conversion
Common Stock
[F3]2026-03-15+3,248→ 73,545 total - Tax Payment
Common Stock
2026-03-15$125.85/sh−1,795$225,901→ 71,750 total - Exercise/Conversion
Common Stock
[F3][F4]2026-03-15−3,248→ 0 totalExercise: $0.00From: 2026-03-15Exp: 2026-03-15→ Common Stock (3,248 underlying) - Exercise/Conversion
Performance Shares
[F1][F5][F2]2026-03-15−11,400→ 0 totalExercise: $0.00From: 2026-03-15Exp: 2026-03-15→ Common Stock (11,400 underlying)
Footnotes (5)
- [F1]These Securities are Performance-based Restricted Stock Units (PRSU).
- [F2]Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.
- [F3]These securities are Restricted Stock Units.
- [F4]There is neither a purchase price nor an exercise price for the Restricted Stock Units.
- [F5]There is neither a purchase price nor an exercise price for the PRSUs.